text:["Active ingredient(s): Tobramycin","Indications: For CF patients aged 6 years and older with <i> Pseudomonas aeruginosa </i> infections","Mechanism: Aminoglycoside antibiotic disrupts bacterial protein synthesis, leading to the death of the pathogen","Administration: Inhalation of antibiotic via nebuliser, typically taken twice daily in 28-day cycles","Approval: Approved by the EMA in 2011 [14]"]
text:["Active ingredient(s): Tobramycin",<>Indications: For CF patients aged 6 years and older with <i> Pseudomonas aeruginosa </i> infections</>,"Mechanism: Aminoglycoside antibiotic disrupts bacterial protein synthesis, leading to the death of the pathogen","Administration: Inhalation of antibiotic via nebuliser, typically taken twice daily in 28-day cycles","Approval: Approved by the EMA in 2011 [14]"]